Trust Signals
Key Takeaways
- Tesamorelin (Egrifta SV) is FDA-approved at 2 mg/day subcutaneous injection and reduced trunk visceral fat by roughly 15 to 18 percent versus placebo at 26 weeks in HIV-lipodystrophy RCTs.
- It requires a prescription in the United States. Compounding is legally restricted because an FDA-approved reference product exists.
- The peptide's N-terminal trans-3-hexenoic acid modification distinguishes it from sermorelin and is the reason for its longer half-life compared to native GHRH.
- WADA prohibits it for competitive athletes under S2 regardless of medical justification outside a Therapeutic Use Exemption.
- Off-label use for body composition in non-HIV adults has some supporting data but no large-scale RCT; the evidence quality is Low to Moderate.
What Is Tesamorelin and Where Can You Get It Near You?
If you are searching for tesamorelin peptide near me, the honest answer is that legitimate access requires a licensed prescriber, a valid diagnosis or clinical indication, and a pharmacy that can legally dispense or compound it. Tesamorelin is not a supplement, not available over the counter, and not legally purchasable from gray-market research peptide vendors for human use. Finding it locally means finding a clinic or physician who can prescribe it, not a supplement shop.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What exactly is tesamorelin?
- What does the evidence actually show?
- How does tesamorelin work, with real numbers?
- What most pages get wrong about tesamorelin
- What is the legal status near me?
- How does tesamorelin compare to alternatives?
- Dosing, reconstitution, and storage
- Real risks and contraindications
- Label and COA literacy: how to judge a source
- FAQ
- Sources
What Exactly Is Tesamorelin?
Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), a 44-amino-acid hypothalamic peptide. The drug version adds a trans-3-hexenoic acid group to the alpha-amino terminus of the full GHRH(1-44) sequence. This modification stabilizes the molecule against enzymatic degradation by dipeptidyl peptidase IV (DPP-IV), extending its plasma half-life compared to native GHRH. It was developed by Theratechnologies and received FDA approval in November 2010 under the brand name Egrifta, later reformulated as Egrifta SV (a more concentrated, stable formulation approved in 2019).
The sole FDA-approved indication is reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. All other applications, including general obesity, anti-aging, or athletic performance, are off-label.
What Does the Evidence Actually Show? (Evidence Ledger)
| Claim | Best Evidence Type | Key Source / Trial | Effect Direction | Confidence |
|---|---|---|---|---|
| Reduces trunk visceral fat in HIV lipodystrophy | Human RCT (Phase 3) | Falutz et al. NEJM 2007; FDA pivotal trials | Positive, meaningful | High |
| Raises IGF-1 levels | Human RCT | Falutz et al. NEJM 2007 | Positive (IGF-1 rises) | High |
| Reduces visceral fat in non-HIV adults | Small human trials | Stanley et al. J Clin Endocrinol Metab 2012 | Positive, modest | Moderate |
| Improves cognitive function | Small RCT (older adults) | Baker et al. JAMA Neurol 2012 | Positive signal, limited sample | Low |
| Improves athletic performance in healthy adults | Mechanism extrapolation only | None | Speculative | Very Low |
| Anti-aging or longevity benefits | No clinical trials | None | Speculative | Very Low |
| Increases risk of glucose intolerance | Human RCT (adverse events) | FDA label, Egrifta SV prescribing information | Negative (risk increases) | High |
How Does Tesamorelin Work? Specific Numbers, Honest Caveats
Tesamorelin binds pituitary GHRH receptors (a G-protein-coupled receptor encoded by the GHRHR gene) and stimulates pulsatile growth hormone secretion. GH is then released into systemic circulation, travels to the liver, and triggers synthesis of insulin-like growth factor 1 (IGF-1). IGF-1 exerts direct lipolytic effects on visceral adipose tissue, particularly abdominal fat depots.
In the pivotal Falutz et al. (NEJM 2007) Phase 3 trial in HIV-positive patients, tesamorelin 2 mg/day for 26 weeks reduced trunk fat (measured by dual-energy X-ray absorptiometry) by approximately 15 to 18 percent compared to placebo. IGF-1 levels rose significantly compared to baseline. The sample sizes in that program were in the hundreds of patients.
The trans-3-hexenoic acid modification at the N-terminus blocks DPP-IV cleavage at the His-Ala bond, the primary degradation site for endogenous GHRH. Native GHRH has a plasma half-life measured in minutes. Tesamorelin's half-life is extended, but still relatively short (on the order of tens of minutes in humans), which is why once-daily dosing rather than weekly dosing is required. This is a mechanistic fact, not a pharmacokinetic argument for more frequent dosing by itself.
What this mechanism does NOT prove: Elevated GH and IGF-1 do not automatically translate to muscle gain, fat loss in non-visceral compartments, cognitive improvement, or longevity in healthy people. GH/IGF-1 elevation is also associated with increased cancer cell proliferation risk in the presence of occult malignancy, a reason the FDA label carries a contraindication for active or suspected malignancy.
What Most Pages About Tesamorelin Get Wrong
A second omission: most pages do not mention that the fat loss seen in trials reverses after discontinuation. The Falutz group showed that patients who stopped tesamorelin regained a substantial portion of the lost visceral fat within weeks to months. This is not a flaw unique to tesamorelin; it reflects the biology of GH-dependent lipolysis, but it has major practical implications for cost, ongoing prescription access, and risk-benefit decisions over years.
Third: bioavailability after subcutaneous injection is meaningful but not 100 percent. Peptides of this molecular weight (approximately 5135 Da for tesamorelin) are subject to subcutaneous proteolysis before systemic absorption. Injection technique, site rotation, and avoiding lipohypertrophic tissue matter clinically.
What Is the Legal Status When Searching Tesamorelin Peptide Near Me?
In the United States, tesamorelin is a Schedule-unscheduled prescription drug (not a controlled substance, but still requiring a prescription). The legal pathways to access it locally are:
- Brand product (Egrifta SV): Prescribed by a physician, dispensed by a specialty pharmacy. Primarily reimbursable under HIV-related diagnoses.
- Compounded version: Legally constrained as described above. If a local clinic offers this, ask for the dispensing facility's 503B FDA registration number and verify it at fda.gov/drugs/human-drug-compounding.
- Research chemical vendors: Sell "for research only, not for human use." Purchasing from these sources for human injection is outside labeled use, likely violates FTC rules, and carries significant safety risk (no sterility guarantee, no verified purity).
Outside the US: regulatory status varies by country. Some countries allow licensed physicians to import or compound GHRH analogues. Always verify local law before seeking access.
How Does Tesamorelin Compare to Alternatives?
| Agent | Class | FDA Approved? | VAT Reduction Evidence | Half-life | Where Tesamorelin Loses |
|---|---|---|---|---|---|
| Tesamorelin (Egrifta SV) | GHRH analogue | Yes (HIV lipodystrophy) | High (Phase 3 RCT) | Minutes to tens of minutes | Cost, reversal on discontinuation, restricted compounding |
| Sermorelin | GHRH analogue (29 AA) | No (withdrawn for growth failure) | Very Low (no robust RCT) | Less than 10 minutes | More established safety and VAT data for tesamorelin |
| CJC-1295 | GHRH analogue (DAC) | No | Very Low (animal/small human) | Days (DAC form) | Tesamorelin has far stronger human evidence |
| Semaglutide (Ozempic/Wegovy) | GLP-1 agonist | Yes (obesity, T2DM) | High (Phase 3 RCTs, total body fat including VAT) | Approx. 1 week | Tesamorelin loses on total fat loss magnitude, evidence breadth, ease of access |
| Lifestyle intervention (diet and exercise) | Non-pharmacological | N/A | High (meta-analyses) | N/A | Tesamorelin has no cost, no injection burden, no drug interactions |
The honest conclusion: for the approved HIV-lipodystrophy indication, tesamorelin is clinically meaningful and well-evidenced. For general body composition in people without HIV or documented GH deficiency, semaglutide has substantially more evidence, broader approval, and better insurance coverage. Tesamorelin is not the obvious first-line choice for most people searching for it locally.
Dosing, Reconstitution, and Storage: Operational Details
FDA-approved dose: 2 mg subcutaneous injection once daily. Injection site is the abdomen. Rotate sites to avoid lipohypertrophy.
Reconstitution (Egrifta SV): The 2 mg/0.36 mL formulation is a ready-to-use solution that does not require reconstitution. Older Egrifta required lyophilized powder to be reconstituted with supplied sterile water. If you are using a compounded lyophilized vial, inject the supplied diluent slowly down the side of the vial wall, swirl gently (do not shake), and inspect for clarity before drawing.
Storage: Refrigerate at 2 to 8 degrees Celsius before first use. Do not freeze. Once reconstituted (lyophilized formulations), use within the window specified by the pharmacy, typically within 24 hours. Heat denatures the peptide bond stability and the trans-3-hexenoic acid modification offers no protection against thermal denaturation, only enzymatic. This is why storing a reconstituted peptide at room temperature for days before use is a real problem, not a minor one.
What degradation looks like: Visible particulates, cloudiness, or a yellow tint in a solution that should be clear. Discard immediately. You cannot test potency at home; if storage was compromised, assume potency loss.
Real Risks and Contraindications
From the FDA Egrifta SV prescribing information:
- Injection site reactions: Most common adverse event in trials. Erythema, pruritus, pain, and induration at the injection site.
- Fluid retention: Peripheral edema, arthralgia, myalgia. These are GH-class effects.
- Glucose intolerance: GH is counter-regulatory to insulin. Tesamorelin can impair glucose metabolism. Monitoring is warranted in patients at risk for diabetes.
- Malignancy risk: IGF-1 promotes cell proliferation. Contraindicated in patients with active malignancy or those with a recent history of malignancy.
- Pituitary insufficiency: Contraindicated if pituitary tumor, surgery, or radiation has disrupted the GHRH-GH axis.
- Pregnancy: Contraindicated. Category X equivalent risk based on animal data.
Antibody formation to tesamorelin has been observed in clinical trials. The FDA label notes that anti-tesamorelin antibodies developed in a portion of participants, though most retained efficacy. This is a real pharmacological consideration for long-term users that almost no medspa blog discusses.
Label and COA Literacy: How to Judge What You Are Getting
If you access tesamorelin through any channel (brand, compounded pharmacy, or otherwise), here is what a legitimate product should demonstrate:
| Parameter | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | Above 98 percent for injectable grade | Purity below 95 percent or no purity data |
| Molecular weight confirmation | Approximately 5135 Da by mass spectrometry | No MS data provided |
| Sterility testing | USP sterility test passed, documented on COA | No sterility test; "research use only" label |
| Endotoxin (LAL test) | Below USP limits for parenteral products | Not tested or not disclosed |
| Labeled concentration | Matches actual tested content within a reasonable tolerance | Labeled only, not confirmed by assay |
| Dispensing facility | FDA-registered 503B outsourcing facility or licensed retail pharmacy | No pharmacy listed; shipped from overseas; no Rx required |
The chemistry reason sterility matters here specifically: tesamorelin is injected subcutaneously, bypassing the gut's bacterial filtration. A non-sterile product introduces Gram-negative bacterial endotoxins that cause fever, systemic inflammation, and sepsis risk entirely independent of the peptide's activity.
FAQ
Can I get tesamorelin peptide near me without a prescription?
No. Tesamorelin (brand name Egrifta) is an FDA-approved prescription drug. In the United States, it requires a valid prescription from a licensed prescriber. Obtaining it without one is illegal. Compounded versions also require a prescription under federal law.
What is tesamorelin approved to treat?
The FDA approved tesamorelin in 2010 specifically for reducing excess abdominal fat (lipodystrophy) in HIV-positive adults on antiretroviral therapy. It is not FDA-approved for general body composition, anti-aging, or athletic performance.
How does tesamorelin work mechanistically?
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors, stimulating pulsatile GH secretion. GH then triggers hepatic IGF-1 production. The net effect is lipolysis in visceral adipose tissue, particularly in the trunk.
What dose is used and how is it given?
The FDA-approved dose is 2 mg subcutaneously once daily into the abdomen. Lyophilized powder must be reconstituted with supplied sterile water immediately before injection. Off-label protocols used in clinical research have ranged from 1 mg to 2 mg daily.
How long does tesamorelin take to work?
In the pivotal HIV-lipodystrophy trials, statistically significant trunk fat reduction was measured at 26 weeks. Visceral adipose tissue (VAT) decreased by roughly 15 to 18 percent versus placebo in those studies. Effects reverse after discontinuation within months.
Is tesamorelin the same as sermorelin or CJC-1295?
All three are GHRH analogues but are chemically distinct. Tesamorelin has the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus that extends its half-life. Sermorelin is a 29-amino-acid truncated fragment. CJC-1295 uses a drug affinity complex to bind albumin, extending action further. Only tesamorelin is FDA-approved.
What are the real risks of tesamorelin?
The FDA label lists injection-site reactions (most common), fluid retention, arthralgia, myalgia, glucose intolerance, and potential progression of malignancies due to IGF-1 elevation. It is contraindicated in active malignancy, pregnancy, and pituitary disruption from prior surgery or radiation.
Can compounding pharmacies legally make tesamorelin?
This is legally contested. The FDA has issued guidance that tesamorelin, as an FDA-approved drug, generally cannot be compounded under Section 503A or 503B of the FDCA. Some 503B outsourcing facilities have nonetheless supplied it. The regulatory landscape is actively shifting; always verify current FDA guidance.
What does a legitimate tesamorelin COA (certificate of analysis) look like?
A legitimate COA from a licensed pharmacy should show HPLC purity (ideally above 98 percent), correct molecular weight confirmation (roughly 5135 Da), endotoxin testing results, sterility testing, and labeled concentration. Research-grade vendors selling non-sterile material are not appropriate for human injection.
Does tesamorelin work for body composition in people without HIV?
Small studies in non-HIV adults with abdominal obesity and relative GH deficiency have shown reductions in VAT, but evidence is limited in sample size and duration. No large RCT has established safety or efficacy in the general healthy adult population. This use is off-label and evidence is Moderate at best.
Is tesamorelin on the WADA prohibited list?
Yes. WADA prohibits GHRH and its analogues under the Peptide Hormones, Growth Factors, and Related Substances category (S2). Any competitive athlete subject to WADA testing should treat tesamorelin as a banned substance regardless of medical prescription.
Sources
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2349-2360. PMID 18057338.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. J Acquir Immune Defic Syndr. 2010;53(3):311-322. PMID 20101189.
- Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID 31711782.
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. J Clin Endocrinol Metab. 2012;97(7):2337-2346. PMID 22508712.
- Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420-1429. PMID 22869065.
- FDA. Egrifta SV (tesamorelin) Prescribing Information. Theratechnologies Inc. Revised 2019. Accessed via fda.gov/drugs.
- FDA. Human Drug Compounding: Guidance Documents. fda.gov/drugs/human-drug-compounding. Accessed 2026.
- WADA. Prohibited List 2024. S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. wada-ama.org. Published 2023.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID 16985923.
- Theratechnologies Inc. Egrifta SV product monograph. 2019.
Footer Disclaimers
Platform: FormBlends is an educational reference platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before initiating, changing, or stopping any medication or peptide therapy.
Research Compound or Compounded Medication: Tesamorelin sold outside of FDA-approved brand labeling (Egrifta SV) may be a compounded medication subject to specific federal and state legal requirements. FormBlends does not sell, dispense, or broker tesamorelin in any form.
Results: Individual outcomes vary. The clinical results cited on this page are from controlled trials in specific populations (primarily HIV-positive adults with lipodystrophy). They may not generalize to other populations or conditions.
Trademark: Egrifta and Egrifta SV are registered trademarks of Theratechnologies Inc. WADA is a trademark of the World Anti-Doping Agency. FormBlends has no affiliation with either organization.